Issues in the treatment of, hypertension:Current and future perspectives

Cardiology (Switzerland)

Volumn 88, Issue , 1997, Pages 47-53

  Hansson, Lennart ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Angiotensin converting enzyme; Antihypertensive treatment; Calcium channel blockers; Hypertension; Inhibitors Intervention trials

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL PLUS CHLORTALIDONE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLOROTHIAZIDE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GANGLION BLOCKING AGENT; GUANETHIDINE; HEXAMETHONIUM; HYDRALAZINE; INDAPAMIDE; LISINOPRIL; LOSARTAN; METOPROLOL; NISOLDIPINE; PERINDOPRIL; PINDOLOL; PRAZOSIN; PROPRANOLOL; RESERPINE; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; ARTERIAL PRESSURE; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; HYPERTENSION; MALIGNANT HYPERTENSION; META ANALYSIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; SWEDEN; UNITED STATES;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS; HUMANS; HYPERTENSION; INTERVENTION STUDIES; MORBIDITY; SURVIVAL RATE;

EID: 0031021353     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000177463     Document Type: Article

References (45)

1. Pickering GW, Cranston WI, Pears MA: The Treatment of Hypertension. Springfield. Thomas, 1961.
2. Dustan HP. Schneckloth RE, Corcoran AC. Page IH: The effectiveness of long-term treatment of malignant hypertension. Circulation 1958;18:644-651.
3. Harington M. Kincaid-Smith P. McMichael J: Results of treatment in malignant hypertension. A 7-year experience in 94 cases. BMJ 1959:2:969-980.
4. Bjòrk S, Sanncrstcdt R. Angcrvall G. Hood B: Treatment and prognosis in malignant hypertension. Clinical follow-up study of 93 patients on modem medical treatment. Acta Med Scand 1960:166:175-187.
5. Sokolow M. Pcrloff D: Five years survival of consecutive patients with malignant hypertension treated with antihypertensive agents. Am J Cardiol 1960:60:858-863.
6. Möhler ER Jr, Freis ED: Five years' survival of patients with malignant hypertension treated with antihypertensive agents. Am Heart J 1960:60:329-335.
7. Hodge JV. McQueen EG, Smirk H: Results of hypotensive therapy in arterial hypertension based on experience with 497 patients treated and 156 controls observed for periods from I to 8 years. BMJ 1961;1:1-7.
8. North JDK. Williams JCP, Howie RN: Severe hypertension treated with ganglion-blocking drugs in a general hospital. BMJ 1961; 1:1426- 1429.
9. Farmer RG, Gifford RW, Hines EA; Effect of medical treatment of severe hypertension. A follow-up of 161 patients with group 3 and group 4 hypertension. Arch Intern Med 1963: 112:118-128.
10. Hood B, Ômdahl G, Bjôrk S: Survival and mortality in malignant (grade IV) and grade III hypertension. Trends in consecutive, actively treated groups. Acta Med Scand 1970:187: 291-302.
11. Gudbrandsson T, Hansson L. Herlitz H, Andréa L: Malignant hypertension-Improving prognosis in a rare disease. Acta Med Scand 1979;206:495-499.
12. Kincaid-Smith P: Malignant Hypertension. J Hypcrtens 1991:9:893-899.
13. Sytkowski PA. D'Agostino RB. Belanger AJ. Kannel WB: Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. Circulation 1996: 93:697-703.
14. Ribacke M. Tibblin G. Rosengrcn A, Eriksson H: Is hypertension changing? Blood pressure development in cohorts of 50-vear-old men between 1963and 1993. Blood Press 1996:5:133-137.
15. Collins R, Peto R. Mac Mahon S, Herbert P. Fiebach NH. Eberlein KA, Godwin J, Quizil-bash N, Taylor JO, I lennekens CH: Blood pressure. stroke and coronary heart disease. 2. Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990:335:827-838.
16. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the systolic hypertension in the elderly program. JAMA 1991:265:3255-3264.
17. Dahlof B. Lindholm LH. Hansson L. Schcrstén B, Ekbom T. Wester P-O: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypcrtension). Lancet 1991;338:1281-1285.
18. MRC Working Party: Medical Research Council trial of treatment of hypertension in older adults: Principle results. BMJ 1992:304:405-412.
19. Amery A. Birkenhâger W. Brixko P. Bulpitt C. Clement D. De Schaepddryver A. Dollerv C, Fagard R, Forctte F. Forte J. Harndy R, Henry JF. Joossens JV. Leonetti G. Lund-Johansen P. O'Malley K. Petrie J, Strasser T. Tuomilehto J, Williams B: Mortality and morbidity results from the European Working Party on High Blood Pressure in the elderly trial. Lancet 1985; i: 1351-1354.
20. Coope J. Warrcndcr TS: Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986:293:1145-1151.
21. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on mortality in hypertension. III. Influence of age. diastolic blood pressure, and prior cardiovascular disease; further analysis of side effects. Circulation 1972:45:991-1004.
22. Hypertension Detection and Follow-Up Program Cooperative Group: Five-year findings of the HDFP. II. Mortality by race, sex and age. JAMA 1979;242:2572-2577.
23. The Management Committee: Treatment of mild hypertension in the elderly: A study initiated and administered by the National Heart Foundation of Australia. Med J Aust 1981:2: 398-402.
24. Zanchetti A, Chalmers J. Arakawa K. Gyarfas I, Hamct P. Hansson L. Julius S, MacMahon S. Mancia G. Ménard J, Omae T. Reid J, Safar M: The 1993 guidelines for the management of mild hypertension: Memorandum from a WHO/ISH meeting. Blood Press 1993:2:86-100.
25. Johannesson M. Dahlof B. Lindholm LH, Ekbom T, Hansson L. Oden A, Schcrstén B, Wester P-O. Jonsson B: Treatment of hypertension in the elderly is cost effective-An analysis of the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). J Intern Med 1993;234:317-323.
26. Hansson L, Svensson A. Dahlof B, Eggertsen R: Drug treatment of hypertension; in Robertson JIS (ed): Handbook of Hypertension. Amsterdam, Elsevier. 1992, vol 15, pp 655-708.
27. Beyer KH: The mechanism of action of chlorothiazide. Ann NY Acad Sci 1958;71:363-371.
28. The Joint National Committee on Detection. Evaluation, andTreatmcntofHigh Blood Pressure: The fifth report of the Joint National Committee on Detection. Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153:154-183.
29. Hansson L: The benefits of lowering elevated blood pressure-A critical review of the results of the major intervention trials in hypertension. J Hypcrtens 1996:14:537-544.
30. The CAPPP Group: The Captopril Prevention Project: A prospective intervention trial of angiotensin converting enzyme inhibition in the treatment of hypertension. J Hypcrtens 1990:8: 985-990.
31. Hansson L. Hedner T. Dahlof B: Prospective Randomized Open Blinded End-Point (PROBE) Study: A novel design for intervention trials. Blood Press 1992:1:113-119.
32. The NORDIL Study Group: The Nordic Dil-tiazem Study. An intervention study in hypertension comparing calcium antagonist based treatment with conventional therapy. Blood Press 1993;2:312-321.
33. Dahlof B, Hansson L, Lindholm LH. Scherstén B, Wester P-O, Ekbom T. Hcdner T. De Faire U: STOP-Hypertcnsion-2: A prospective intervention trial of‘newer’ versus 'older' treatment alternatives in old patients with hypertension. Blood Press 1993;2:136-141.
34. Amery A, Birkenhagcr W. Bulpitt CJ. Clement D. De Lceuw P. Dollery CT. Fagard R, Fletcher A. Forettc F, Leonetti G: SYST-EUR. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organisation. Aging 1991:3:287-302.
35. Shanghai Trial of Nifedipine in the Elderly (STONE) (abstract 192A). Am J Hvpertens 1996;9.
36. Cushman WC, for the ALLHAT Research Group: The antihvpcrtensivc and lipid lowering treatment to prevent heart attack trial (ALLHAT)-Design and initial characteristics (abstract 4). Hypertension 1995:25.
37. Skoog L, Nilsson L. Palmertz B. Andreasson L-A, Svanborg A: A population-based study of dementia in 85-vear-olds. N Engl J Med 1993: 328:153-158.
38. Hachinski V: Preventive senility: A call for action against the vascular dementias. Lancet 1992:340:645-648.
39. Skoog I, Lemfelt B, Landahl S, Palmertz B, Andreasson L-A. Nilsson L. Persson G. Odén A. Svanborg A: 15 year longitudinal study of blood pressure and dementia. Lancet 1996; 347:1141-1145.
40. Hansson L: Analysis of treatment outcomes -Whv is benefit not larger? Clin Exp Hypertens 1989:A11:753-760.
41. The BBB Study Group: The BBB Study: A prospective randomized study of intensified anti-hypertensive treatment. J Hvpertens 1988:6: 693-697.
42. Hansson L. for the BBB Study Group: The BBB Study: The effect of intensified antihvper-tcnsivc treatment on the level of blood pressure, side effects, morbidity and mortality in 'well-treated' hypertensive patients. Blood Press 1994;3:248-254.
43. The HOT Study Group: The Hypertension Optimal Treatment (HOT) Study-A prospective study of the optimal therapeutic goal and the value of low-dose aspirin in antihypertensive treatment. Blood Press 1993:2:113-119.
44. Hansson L. Zanchetti A. for the HOT Study Group: The Hypertension Optimal Treatment (HOT) Study-Patient characteristics: Randomization, risk profiles, and early blood pressure results. Blood Press 1994:3:322-327.
45. Hansson L. Zanchetti A. for the HOT Study Group: The Hypertension Optimal Treatment (HOT) Study: 12-Month data on blood pressure and tolerability. With special reference to age and gender. Blood Press 1995;4:313-319.